

*Organic & Biomolecular Chemistry*

**Supporting Information**

**Oligonucleotide modifications enhance probe stability for single cell transcriptome in vivo analysis (TIVA)**

S. B. Yeldell<sup>a</sup>, B. K. Ruble<sup>a</sup>, and I. J. Dmochowski<sup>a</sup>


<sup>a</sup>Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, PA 19104-6323, USA. E-mail: ivandmo@sas.upenn.edu

Tel: +1 215-898-6459

**Contents:**


<b>Figure S1</b>	<b>S2</b>
RP-HPLC purification of crude 22/9/9 GC probe after cleavage	
<b>Figure S2</b>	<b>S3</b>
AX-HPLC purification of 22/9/9 GC probe after conjugation to (D-Arg) <sub>9</sub> cell-penetrating peptide	
<b>Figure S3</b>	<b>S4</b>
RP-HPLC purification of crude PS-22/9/9 probe after solid-phase synthesis and cleavage	
<b>Figure S4</b>	<b>S5</b>
FRET efficiencies of 18/7/7 and 22/9/9 TIVA probes in buffer, pre-photolysis	
<b>Figure S5</b>	<b>S6</b>
RP-HPLC purification of crude 22/9/9 GC probe after solid-phase synthesis and cleavage	
<b>Figure S6</b>	<b>S7</b>
AX-HPLC purification of 22/9/9 probe after conjugation to (D-Arg) <sub>9</sub> cell-penetrating peptide	
<b>Figure S5</b>	<b>S8</b>
RP-HPLC purification of cleaved 18/7/7 TIVA syntheses before and after protocol improvements	
<b>Figure S8</b>	<b>S9</b>
ESI-MS analysis of 22/9/9 +(D-Arg) <sub>9</sub> TIVA	

**Figure S1.** RP-HPLC purification of crude 22/9/9 GC probe after solid-phase synthesis and cleavage




Separation was performed on C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with the product eluting at roughly 28 min.

**Figure S2.** AX-HPLC purification of 22/9/9 GC probe after conjugation to (D-Arg)<sub>9</sub> cell-penetrating peptide




Separation was performed on Source 15q ion-exchange column under a gradient of increasing NaClO<sub>4</sub> in 1:1 formamide:Tris-HCl buffer, with the product eluting at roughly 24 min.

**Figure S3.** RP-HPLC purification of crude PS-22/9/9 probe after solid-phase synthesis and cleavage




Separation was performed on C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with the product eluting at roughly 27 min.

**Figure S4.** FRET efficiencies of 18/7/7 and 22/9/9 TIVA probes in buffer, pre-photolysis




FRET efficiencies were measured for both probes at 1.0  $\mu\text{M}$  in 1x STE buffer. 18/7/7 and 22/9/9 TIVA probes were synthesized according to [19].

**Figure S5.** RP-HPLC purification of crude 22/9/9 GC probe after solid-phase synthesis and cleavage




Separation was performed on C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with the product eluting at roughly 50 min.

**Figure S6.** AX-HPLC purification of 22/9/9 probe after conjugation to (D-Arg)<sub>9</sub> cell-penetrating peptide




Separation was performed on Source 15q ion-exchange column under a gradient of increasing NaClO<sub>4</sub> in 1:1 formamide:Tris-HCl buffer, with the product eluting at roughly 24 min.

**Figure S7.** RP-HPLC purification of cleaved 18/7/7 TIVA syntheses before and after protocol improvements



RP-HPLC purification of six different 18/7/7 TIVA probe syntheses, three before (A) and three after (B) protocol improvements, resulting in more consistent syntheses with higher yield. Separation was performed on a C-18 column under a gradient of increasing acetonitrile in 0.5 M.

**Figure S8.** ESI-MS analysis of 22/9/9 +(D-Arg)<sub>9</sub> TIVA



ESI-MS verified the product mass (16,913 Da predicted, 16,912 Da observed). The principal impurity corresponded to TIVA product with one missing 2'F-U (-307 Da), which is not expected to significantly impact probe performance.